Last reviewed · How we verify
Urfamicin (thiamphenicol glycinate)
Urfamicin (generic name: thiamphenicol glycinate) is a thiamphenicol glycinate drug. It is currently in unknown development.
Urfamicin works by inhibiting protein synthesis in bacteria.
Urfamicin is a small molecule. Its mechanism of action is not specified in the provided information.
At a glance
| Generic name | thiamphenicol glycinate |
|---|---|
| Drug class | thiamphenicol glycinate |
| Therapeutic area | Infectious Disease |
| Phase | unknown |
Mechanism of action
Imagine your body's cells are like factories that make proteins to keep you healthy. Bacteria are like tiny invaders that try to take over these factories. Urfamicin is a special tool that blocks the bacteria's ability to make proteins, helping to stop the infection.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Urfamicin CI brief — competitive landscape report
- Urfamicin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Urfamicin
What is Urfamicin?
How does Urfamicin work?
What is the generic name of Urfamicin?
What drug class is Urfamicin in?
What development phase is Urfamicin in?
Related
- Drug class: All thiamphenicol glycinate drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing